Clay Siegall: The Brain Behind Cancer-Based Genetic Research

In January 2013, Mirna Therapeutics appointed the chairperson and present CEO of Seattle Genetics, Clay Siegall to its long list of Board of Directors as an outside director. The rich cancer research history that Clay possesses was seen as the main driving force towards his appointment by Mirna Therapeutics CEO, DR. Paul Lammers. Though both
Continue reading Clay Siegall: The Brain Behind Cancer-Based Genetic Research